Skip to main content

Advertisement

SpringerLink
Log in

Predictors of Poor Outcome in ANCA-Associated Vasculitis (AAV)

  • Vasculitis (L Espinoza, Section Editor)
  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

It is important to recognize factors that might predict poor outcome and prognosis in patients with AAV. The predictors reported in the literature encompass genetic, histopathological, and clinical ones. Genetic studies (genetic predictors) have found genes that are associated with prediction of poor response to treatment, deterioration of renal function, and risk of mortality. Histopathological studies (histopathological predictors) have shown that sclerotic renal lesions are associated with increased risk of progression to end-stage renal disease and death. Lastly, scores (clinical predictors) obtained with tool as FFS, Maldini risk score, VDI, and emerging new biomarkers could potentially be helpful in assessment of prognosis in the future.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, has been highlighted as: • Of importance •• Of major importance

  1. Kallenberg CG. Key advances in the clinical approach to ANCA-associated vasculitis. Nat Rev Rheumatol. 2014;10:489–93.

    Article  Google Scholar 

  2. • Lyons P, Rayner T, Trivedi S, et al. Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med. 2012;367:214–23. This genome wide association study in AAV patients shows that there are significant genetic contribution to pathogenesis of disease and distinct genetic associations with GPA and MPA.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Ugarte-Gil MF, Espinoza LR. Genetic of ANCA-associated vasculitides. Curr Rheumatol Rep. 2014;16(7):428.

    Article  PubMed  Google Scholar 

  4. Chang DY, Luo H, Zhou XJ, et al. Association of HLA genes with clinical outcomes of ANCA-associated vasculitis. Clin J Am Soc Nephrol. 2012;7:1293–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Persson U, Gullstrand B, Pettersson A, et al. A candidate gene approach to ANCA-associated vasculitis reveals links to the C3 and CTLA-4 genes but not to the IL1-Ra and Fcγ-RIIa genes. Kidney Blood Press Res. 2013;37:641–8.

    Article  CAS  PubMed  Google Scholar 

  6. •• Cao Y, Liu K, Tian Z, et al. PTPN22 R620W polymorphism and ANCA disease risk in white populations: a meta-analysis. J Rheum. 2015;42(2):292–9. A meta-analysis of four studies of the PTPN22 620W allele confers susceptibility to the occurrence and development of ANCA disease in whites, with specific evidence among subsets with GPA, MPA, and PR3 ANCA.

    Article  CAS  PubMed  Google Scholar 

  7. •• Graysson PC, Carmona-Rivera C, Xu L, et al. Neutrophil-related gene expression and low-density granulocytes associated with disease activity and response to treatment in ANCA-associated vasculitis. Arthritis and Rheum. 2015;67(7):1922–32. Recently published study using serum from the RAVE study, which investigated biomarkers involved in the pathophysiology of ANCA-associated vasculitis and sought to determine if LDG contribute to gene expression signatures in AAV. Granulocyte-related gene expression was associated with disease activity and relatively poor response to treatment in AAV.

    Article  Google Scholar 

  8. Rahmattulla C, Berden A, Bajema I. Kidneys in ANCA-associated vasculitis: what to learn from biopsies? Press Med. 2013;42(4):563–5.

    Article  Google Scholar 

  9. Berden A, Ferrario F, Hagen EC, et al. Histopathological classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol. 2010;21:1628.1636.

    Google Scholar 

  10. Chang DY, Wu LH, Liu G, et al. Re-evaluation of the histopathologic classification of ANCA-associated glomerulonephritis: a study of 121 patients in a single center. Nephrol Dial Transplant. 2012;27(6):2343–9.

    Article  PubMed  Google Scholar 

  11. Muso E, Endo T, Itabashi M, et al. Evaluation of the newly proposed simplified histological classification in Japanese cohorts of myeloperoxidase-anti-neutrophil cytoplasmic antibody-associated glomerulonephritis in comparison with other Asian and European cohorts. Clin Exp Nephrol. 2013;17:659–62.

    Article  CAS  PubMed  Google Scholar 

  12. Ellis CL, Manno R, Racusen LC, et al. New histopathologic classification of anti-neutrophil cytoplasmic antibody associated pauci-immune glomerulonephritis: correlation with renal outcome (Abstract). J Am Soc Nephrol. 2012;23:711A.

    Google Scholar 

  13. Ford S, Polkinghorne K, Longano A, et al. Renal function and sclerotic glomerular injury predict poor prognosis in patients presenting with anti-neutrophil cytoplasmic antibody associated vasculitis (Abstract). J Am Soc Nephrol. 2012;23:711A.

    Google Scholar 

  14. Shah S, Havill J, Rahman MH, Geetha D. A historical study of American patients with anti-neutrophil cytoplasmic antibody negative pauci-immune glomerulonephritis. Clin Rheumatol 2016;35(4):953–960.

  15. Hanaoka H, Ota Y, Takeuchi T, Kuwana M. Poor renal outcomes in patients with anti-neutrophil cytoplasmic antibody-associated crescentic glomerulonephritis and normal renal function at diagnosis Clin Rheumatol 2016;35(2):495–500.

  16. Tanna A, Guarino L, Tam FWK, et al. Long-term outcome of anti-neutrophil cytoplasm antibody-associated glomerulonephritis: evaluation of the international histological classification and other prognostic factors. Nephrol Dial Transplant. 2015;30:1185–92.

    Article  PubMed  Google Scholar 

  17. Ford GSL, Polkinghorne KR, Longano A, et al. Histopathologic and clinical predictors of kidney outcomes in ANCA-associated vasculitis. Am J Kidney Dis. 2014;63(2):227–35.

    Article  PubMed  Google Scholar 

  18. Moroni G, Binda V, Leoni A, et al. Predictors of renal survival in ANCA-associated vasculitis. Validation of a histopathological classification schema and review of the literature. Clin Exp Rheumatol. 2015;33(Supp 89):S56–63.

    Google Scholar 

  19. Guillevin L, Pagnoux C, Seror R, et al. The Five Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitides Study Group (FVSG) cohort. Medicine. 2011;90:19–27.

    Article  PubMed  Google Scholar 

  20. Maldini C, Resche-Rigon M, et al. A risk score for predicting short-term incidence of death or relapse in anti-neutrophil cytoplasmic antibody-associated vasculitis. Press Med. 2013;42((4) part 2):666.

    Article  Google Scholar 

  21. Bhamra K, Luqmani R. Damage assessment in ANCA-associated vasculitis. Curr Rheumatol Rep. 2012;14:494–500.

    Article  CAS  PubMed  Google Scholar 

  22. Ponte C, Sznajd J, ONeill L, Luqmani RA. Optimization of vasculitis disease assessment in clinical trials, clinical care and long-term databases. Clin Exp Rheumatol. 2014;32(sup.85):S118–25.

    Google Scholar 

  23. • Kronbichler A, Kerschbaum J, Grundingler G, et al. Evaluation and validation of biomarkers in granulomatosis with polyangiitis and microscopic polyangiitis. Nephrol Dial Transplant 2015. A systematic literature review was performed, which identified 161 marker molecules. They identified promising biomarkers and proposed a biomarker panel comprising CRP and urinary MCP-1 in patients with AAV and renal involvement.

  24. Grayson PC, Monach PA, Pagnoux C, et al. Value of commonly measured laboratory tests as biomarkers of disease activity and predictors of relapse in eosinophilic granulomatosis with polyangiitis. Rheumatology (Oxford). 2015;54(8):1351–9.

    Article  Google Scholar 

  25. Dejaco C, Oppl B, Monach P, et al. Serum biomarkers in patients with relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss). PLoS One. 2015;10(3):1–8.

    Article  Google Scholar 

  26. Brix S, Stege G, Disteldorf E, et al. CC chemokine ligand 18 in ANCA-associated crescentic glomerulonephritis. J Am Soc Nephrol. 2015;6(9):2105–17.

    Article  Google Scholar 

  27. de Souza A, Abdulahad WH, Sosicka P, et al. Are urinary levels of high mobility group box 1 marker of active nephritis in anti-neutrophil cytoplasmic antibody-associated vasculitis? Clin and Exp Immunol. 2014;178(2):270–8.

    Article  Google Scholar 

  28. Zhang Y, Shi W, Tang S, et al. The influence of cathelicidin LL37 in human anti-neutrophils cytoplasmic antibody (ANCA)-associated vasculitis. Arthritis Res Ther. 2013;15:R161.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Willeke P, Kumpers P, Schluter B, et al. Platelet counts as a biomarker in ANCA-associated vasculitis. Scand J Rheumatol. 2015;44:302–8.

    Article  CAS  PubMed  Google Scholar 

  30. Unizony S, Lim N, Phippard DJ, et al. Peripheral CD5+ B cells in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 2015;67:535–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Md Yusof MY, Vital EM, Das S, et al. Repeat cycles of rituximab on clinical relapse in ANCA-associated vasculitis: identifying B cell biomarkers for relapse to guide retreatment decisions. Ann Rheum Dis. 2015;74:1734–8.

    Article  PubMed  Google Scholar 

  32. Molad Y, Tovar A, Ofer-Shiber S. Association of low serum complement 3 with reduced patient and renal survival in anti-myeloperoxidase-associated small-vessel vasculitis. Nephron Clin Pract. 2014;126:67–74.

    Article  CAS  PubMed  Google Scholar 

  33. Skoglund C, Carlsen AL, Weiner M, et al. Circulating microRNA expression pattern separates patients with anti-neutrophil cytoplasmic antibody associated vasculitis from healthy controls. Clin Exp Rheumatol. 2015;33:S-64–71.

    Google Scholar 

  34. Shi YY, Li ZY, Zhao MH, Chen M. The CD4 lymphocyte count is a better predictor of overall infection than the total lymphocyte count in ANCA-associated vasculitis under corticosteroid and cyclophosphamide regimen: a retrospective cohort. Medicine. 2015;94(18):e843–10.1097.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Tarzi RM, Liu J, Schneiter S, et al. CD14 expression is increased on monocytes in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis and correlates with the expression of ANCA autoantigens. Clin Exp Immunol. 2015;181(1):65–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Cao Y, Tian Z, Li W, et al. Predictors of treatment resistance and relapses in Chinese patients with antineutrophil cytoplasmic antibody-associated disease. J Rheumatol. 2014;41:916–22.

    Article  PubMed  Google Scholar 

  37. Miloslavsky EM, Specks U, Merkel PA, et al. Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 2013;65:2441–9.

    Article  CAS  Google Scholar 

  38. Hassan TM, Hassan AS, Igoe A, et al. Lung involvement at presentation predicts disease activity and permanent organ damage at 6, 12 and 24 months follow-up in ANCA-associated vasculitis. BMC Immunol. 2014;15:20.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Grau RG. Drug-induced vasculitis. New insights and a changing lineup of suspects. Curr Rheumatol Rep 2015

  40. Nakazawa D, Shida H, Tomaru U, Yoshida M, Nishio S, Atsumi T, et al. Enhanced formation and disordered regulation of NETs in myeloperidase-ANCA-associated microscopic polyangiitis. J Am Soc Nephrol. 2014;25:990–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Wang H, Sha L-L, Ma T-T, Zhang L-X, Chan M, Zhao M-H. Circulating levels of neutrophil extracellular traps is not a useful biomarker for assessing disease activity in antineutrophil cytoplasmic antibody-associated vasculitis. PLoS One. 2016;11(2):e0148197.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Servicio de Reumatología, Hospital Central de la Fuerza Aérea, Lima, Perú

    Luis E. Vega

  2. Louisiana State University Health Sciences Center, 433 Bolivar St, New Orleans, LA, 70112, USA

    Luis R. Espinoza

Authors
  1. Luis E. Vega
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Luis R. Espinoza
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Luis E. Vega.

Ethics declarations

Conflict of Interest

Luis E. Vega and Luis R. Espinoza declare that they have no conflict of interest.

Human and Animal Right and Informed Consent

This article does not contain any studies with human and animal subjects performed by any of the authors

Additional information

This article is part of the Topical Collection on Vasculitis

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vega, L.E., Espinoza, L.R. Predictors of Poor Outcome in ANCA-Associated Vasculitis (AAV). Curr Rheumatol Rep 18, 70 (2016). https://doi.org/10.1007/s11926-016-0619-3

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11926-016-0619-3

Keywords

Search

Navigation